Allogeneic Hematopoietic Stem Cell Transplantation
Conditions
Interventions
From each HSCT survivor, we will collect up to 50 mL peripheral blood. For participants <25 kg, the volume of blood will be adjusted to 2 mL per kg bodyweight (2.5% of total blood volume).
Sponsors
Prinses Máxima Center for Pediatric Oncology
Eligibility
Inclusion criteria
Inclusion criteria: - Underwent allogeneic HSCT at age =18 yrs - A minimum survival of 5 years after HSCT. In case a patient has received multiple HSCTs, the last HSCT will be used to determine this 5-year minimum.
Exclusion criteria
Exclusion criteria: - Recipients of a “NiCord” HSCT. NiCord is a clinical trial on the safety and efficacy of transplantation of ex vivo expanded cord blood HSCs. As outcome measures of our study overlap with the outcome of this trial, NiCord recipients will be excluded. - Failure of the HSCT recipient and/or their legal representatives to understand the patient information and informed consent form (either due to intellectual disability or to language problems).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Determine the percentage of HSCT survivors with hematopoietic dysfunction, defined as: (1) cytopenia; (2) clonal hematopoiesis; (3) loss of donor chimerism; (4) bone marrow failure; (5) myelodysplasia; and (6) donor-cell leukemia. | — |
Secondary
| Measure | Time frame |
|---|---|
| Identify clinical determinants of hematopoietic dysfunction in long-term pediatric HSCT survivors compared to those without hematopoietic dysfunction. Analyze the integrity of hematopoiesis at a molecular level (pending funding). | — |
Contacts
Public ContactKonradin Müskens
Princess Máxima Center
Outcome results
None listed